TY - JOUR AU - Bianco, Andrea AU - Campbell, Susan F. M. PY - 2018 TI - Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? JF - Translational Cancer Research; Vol 8, Supplement 2 (March 28, 2019): Translational Cancer Research Y2 - 2018 KW - N2 - Targeting adaptive immunity is a game changer for cancer treatment, revolutionizing lung cancer management. Chemotherapy has been the standard treatment for lung cancer (1-4) until recently when molecular targets including genes harbouring cancer-driving mutations and immune check-points have emerged as targets for new therapies (5-12). With the increasing relevance of ICIs, clinical research is required to define which combination regimens provide the greatest benefits in lung cancer patients. UR - https://tcr.amegroups.org/article/view/25256